| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:51:58 UTC |
|---|
| HMDB ID | HMDB0015390 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Sitagliptin |
|---|
| Description | Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. |
|---|
| Structure | N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (2R)-4-oxo-4-[3-(TRIFLUOROMETHYL)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine | ChEBI | | MK-0431 | ChEBI | | Sitagliptina | ChEBI | | Sitagliptine | ChEBI | | Sitagliptinum | ChEBI | | Sitagliptan | HMDB | | Sitagliptin phosphate | HMDB | | 4-oxo-4-(3-(Trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine | HMDB | | Anhydrous, sitagliptin phosphate | HMDB | | Januvia | HMDB | | Monohydrate, sitagliptin monophosphate | HMDB | | Monohydrate, sitagliptin phosphate | HMDB | | monoPhosphate monohydrate, sitagliptin | HMDB | | Phosphate anhydrous, sitagliptin | HMDB | | Phosphate monohydrate, sitagliptin | HMDB | | Phosphate, sitagliptin | HMDB | | Sitagliptin monophosphate monohydrate | HMDB | | Sitagliptin phosphate anhydrous | HMDB | | Sitagliptin phosphate monohydrate | HMDB |
|
|---|
| Chemical Formula | C16H15F6N5O |
|---|
| Average Molecular Weight | 407.3136 |
|---|
| Monoisotopic Molecular Weight | 407.118079357 |
|---|
| IUPAC Name | (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one |
|---|
| Traditional Name | sitagliptin |
|---|
| CAS Registry Number | 486460-32-6 |
|---|
| SMILES | N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F |
|---|
| InChI Identifier | InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
|---|
| InChI Key | MFFMDFFZMYYVKS-SECBINFHSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Beta amino acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Beta amino acid or derivatives
- Amphetamine or derivatives
- Triazolopyrazine
- Fluorobenzene
- Halobenzene
- Aralkylamine
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Pyrazine
- Benzenoid
- 1,2,4-triazole
- Triazole
- Tertiary carboxylic acid amide
- Heteroaromatic compound
- Azole
- Carboxamide group
- Azacycle
- Organoheterocyclic compound
- Organic nitrogen compound
- Organohalogen compound
- Primary aliphatic amine
- Organic oxide
- Organopnictogen compound
- Organofluoride
- Carbonyl group
- Organic oxygen compound
- Amine
- Organonitrogen compound
- Alkyl halide
- Alkyl fluoride
- Hydrocarbon derivative
- Organooxygen compound
- Primary amine
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.034 g/L | Not Available | | LogP | 1.5 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.18 minutes | 32390414 | | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.11 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.0292 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.39 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 85.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1317.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 222.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 138.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 167.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 95.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 381.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 412.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 277.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 815.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 349.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1155.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 244.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 290.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 296.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 207.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 102.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Sitagliptin,1TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 2794.4 | Semi standard non polar | 33892256 | | Sitagliptin,1TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 2689.1 | Standard non polar | 33892256 | | Sitagliptin,1TMS,isomer #1 | C[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 3168.4 | Standard polar | 33892256 | | Sitagliptin,2TMS,isomer #1 | C[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C | 2943.9 | Semi standard non polar | 33892256 | | Sitagliptin,2TMS,isomer #1 | C[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C | 2830.0 | Standard non polar | 33892256 | | Sitagliptin,2TMS,isomer #1 | C[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C | 3020.6 | Standard polar | 33892256 | | Sitagliptin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 3011.9 | Semi standard non polar | 33892256 | | Sitagliptin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 2912.6 | Standard non polar | 33892256 | | Sitagliptin,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N[C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F | 3220.7 | Standard polar | 33892256 | | Sitagliptin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C(C)(C)C | 3340.0 | Semi standard non polar | 33892256 | | Sitagliptin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C(C)(C)C | 3256.8 | Standard non polar | 33892256 | | Sitagliptin,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N([C@@H](CC(=O)N1CCN2C(=NN=C2C(F)(F)F)C1)CC1=CC(F)=C(F)C=C1F)[Si](C)(C)C(C)(C)C | 3110.1 | Standard polar | 33892256 |
|
|---|
| General References | - Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005 Dec;78(6):675-88. [PubMed:16338283 ]
- Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006 Aug;46(8):876-86. [PubMed:16855072 ]
- Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . [PubMed:18182122 ]
- Pratley RE, Salsali A: Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007 Apr;23(4):919-31. [PubMed:17407649 ]
- Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C: Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag. 2008;4(4):753-68. [PubMed:19065993 ]
- Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R: Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007 Sep;28(6):315-22. [PubMed:17575559 ]
|
|---|